# R1 Clinical-Safety Review — mature_cystic_teratoma_ovary

VERDICT: APPROVE

goldens changed: no (intended: n/a — narrative content, not engine logic)

## 1. Safety
No unsafe, misleading, or absolute statements. Surveillance for small/asymptomatic/imaging-typical
lesions vs surgery for larger/growing/symptomatic/atypical is correctly conditional. Torsion and
rupture are correctly flagged as surgical emergencies. Fertility-sparing cystectomy vs oophorectomy
is framed by age/fertility/viability/bilaterality, not prescribed absolutely. Nothing here would
cause harm if followed. No definitive diagnostic claim that oversteps decision-support.

## 2. Grounding (DeVita/NCCN standard of care)
Consistent with standard of care. The draft is unusually disciplined about attribution: each
non-DeVita claim (surveillance intervals, cystectomy technique, torsion/rupture management, marker
use to exclude a malignant counterpart) is explicitly labelled "general oncology standard, not from
DeVita's section on this disease." The DeVita-attributed claims (benign mixed cystic/solid mass in
the adnexal-mass differential; malignant germ cell tumours treated on the testicular-cancer model
with platinum-based combination chemotherapy; no RT/chemo role for the benign masses) match DeVita.
No fabricated or outdated regimen. The BEP mention is correctly scoped to the malignant counterpart
and marked as a diagnostic boundary, not treatment of the benign lesion.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, or numbered schedule. "bleomycin-etoposide-cisplatin" names drugs
only (permitted). "FIGO stage IA / grade 1-2" are stage/grade descriptors, not doses.

## 4. Scope
Appropriately hedged as decision-support. Referral triggers to gyn-onc are conditional, and the
narrative repeatedly marks the boundary between the benign entity and its malignant look-alikes
rather than issuing directives. The closing "what DeVita is silent on" section is transparent about
sourcing limits.

## 5. Adversarial flags
No `.verdict.md` present at the sidecar path — no outstanding adversarial ISSUES to reconcile.

## Advisory (non-blocking)
- The exception "adjuvant chemotherapy given to all except FIGO stage IA dysgerminoma and stage IA,
  grade 1-2 immature teratoma" is attributed to DeVita. Some sources restrict routine observation to
  stage IA grade 1 immature teratoma. This aside concerns the malignant counterpart (not the benign
  subject of this file) and is hedged as a boundary note, so it is not blocking — but verify the
  grade cutoff against the cited DeVita 12th ed. text; if DeVita says grade 1 only, correct "1-2".
- Minor: the meta-commentary paragraphs are verbose for a KB management field, but that is a clarity
  point, not a safety one.
